Sun Pharmaceutical receives credit ratings from CRISIL and ICRA Back
<P>&nbsp;Sun Pharmaceutical Industries (Sun Pharma)&nbsp;announced that CRISIL has reaffirmed the rating of the company's long term bank facilities at CRISIL AAA and short term bank facilities and commercial paper at CRISIL A1+. </P> <P>CRISIL has placed the ‘Crisil AAA' rating on the long-term bank facilities on ‘Rating Watch with Developing Implications'. This rating action follows Sun Pharma's announcement dated 27 April 2026, about signing a definitive agreement to acquire Organon &amp; Co. (announcement). </P> <P>CRISIL has further communicated that it will remove the rating from watch and announce its final rating action post a comprehensive assessment of this acquisition.</P> <P>Further, ICRA has reaffirmed the rating on the long-term bank facilities for Sun Pharma, at ICRA AAA; Stable and short-term bank facilities and commercial paper at&nbsp;ICRA A1+ after taking note of the announcement.</P>